BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 22230199)

  • 1. Unbiased binding assays for discovering small-molecule probes and drugs.
    Kemp MM; Weïwer M; Koehler AN
    Bioorg Med Chem; 2012 Mar; 20(6):1979-89. PubMed ID: 22230199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery?
    Thiel P; Kaiser M; Ottmann C
    Angew Chem Int Ed Engl; 2012 Feb; 51(9):2012-8. PubMed ID: 22308055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery.
    Hennig M; Ruf A; Huber W
    Top Curr Chem; 2012; 317():115-43. PubMed ID: 21837555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target identification of bioactive compounds.
    Tashiro E; Imoto M
    Bioorg Med Chem; 2012 Mar; 20(6):1910-21. PubMed ID: 22104438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting serpins in high-throughput and structure-based drug design.
    Chang YP; Mahadeva R; Patschull AO; Nobeli I; Ekeowa UI; McKay AR; Thalassinos K; Irving JA; Haq I; Nyon MP; Christodoulou J; Ordóñez A; Miranda E; Gooptu B
    Methods Enzymol; 2011; 501():139-75. PubMed ID: 22078534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of bioactive small molecule target through phenotypic screening.
    Cho YS; Kwon HJ
    Bioorg Med Chem; 2012 Mar; 20(6):1922-8. PubMed ID: 22153994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction to fragment-based drug discovery.
    Erlanson DA
    Top Curr Chem; 2012; 317():1-32. PubMed ID: 21695633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biophysical methods in drug discovery from small molecule to pharmaceutical.
    Holdgate G; Geschwindner S; Breeze A; Davies G; Colclough N; Temesi D; Ward L
    Methods Mol Biol; 2013; 1008():327-55. PubMed ID: 23729258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of laser diode thermal desorption (LDTD) coupled with tandem mass spectrometry (MS/MS) for support of in vitro drug discovery assays: increasing scope, robustness and throughput of the LDTD technique for use with chemically diverse compound libraries.
    Beattie I; Smith A; Weston DJ; White P; Szwandt S; Sealey L
    J Pharm Biomed Anal; 2012 Feb; 59():18-28. PubMed ID: 22071442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical proteomics and its impact on the drug discovery process.
    Miao Q; Zhang CC; Kast J
    Expert Rev Proteomics; 2012 Jun; 9(3):281-91. PubMed ID: 22809207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical comparative assessment of predictions of protein-binding sites for biologically relevant organic compounds.
    Chen K; Mizianty MJ; Gao J; Kurgan L
    Structure; 2011 May; 19(5):613-21. PubMed ID: 21565696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in discovering small molecules to probe protein function in a systems context.
    Doyle SK; Pop MS; Evans HL; Koehler AN
    Curr Opin Chem Biol; 2016 Feb; 30():28-36. PubMed ID: 26615565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on the discovery of small-molecule modulators for epigenetic processes.
    Lu Q; Quinn AM; Patel MP; Semus SF; Graves AP; Bandyopadhyay D; Pope AJ; Thrall SH
    J Biomol Screen; 2012 Jun; 17(5):555-71. PubMed ID: 22392809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent progress in the discovery and development of negative allosteric modulators of mGluR5.
    Lindsley CW; Emmitte KA
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):446-57. PubMed ID: 19562641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and screening of small-molecule α-helix mimetic libraries targeting protein-protein interactions.
    Moon H; Lim HS
    Curr Opin Chem Biol; 2015 Feb; 24():38-47. PubMed ID: 25461722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragment-based lead discovery and design.
    Joseph-McCarthy D; Campbell AJ; Kern G; Moustakas D
    J Chem Inf Model; 2014 Mar; 54(3):693-704. PubMed ID: 24490951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The design, annotation, and application of a kinase-targeted library.
    Xi H; Lunney EA
    Methods Mol Biol; 2011; 685():279-91. PubMed ID: 20981529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of small molecule inhibitors of protein-protein interactions using combined ligand and target score normalization.
    Casey FP; Pihan E; Shields DC
    J Chem Inf Model; 2009 Dec; 49(12):2708-17. PubMed ID: 19994847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Native MS: an 'ESI' way to support structure- and fragment-based drug discovery.
    Vivat Hannah V; Atmanene C; Zeyer D; Van Dorsselaer A; Sanglier-Cianférani S
    Future Med Chem; 2010 Jan; 2(1):35-50. PubMed ID: 21426045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.